Write in a clean editor, then format for Hellenic Journal of Cardiology in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Hellenic Journal of Cardiology is a peer-reviewed journal published by Elsevier, covering Cardiac Valve Diseases and Treatments, Cardiovascular Function and Risk Factors, Cardiac Imaging and Diagnostics.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Hellenic Journal of Cardiology 12 (2023) 45–58.
Formats any DOI in Hellenic Journal of Cardiology style. No sign-up. |
| Publishes research in | Cardiac Valve Diseases and Treatments Cardiovascular Function and Risk Factors Cardiac Imaging and Diagnostics Coronary Interventions and Diagnostics Cardiac Arrhythmias and Treatments |
| ISSN | 1109-9666 |
| Citation impact (2-yr) | 2.35 |
| h-index | 35 |
| i10-index | 260 |
| Total citations | 8,295 |
| Open access | Yes |
| Top institutions publishing here | National and Kapodistrian University of Athens |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
It is well known that cardiovascular disease is the leading cause of mortality in the western societies. A number of risk factors such as family history, diabetes, hypertension, obesity, diabetes, smoking and physical inactivity are responsible for a significant proportion of the overall cardiovascular risk. Interestingly, recent data suggest there is a gradient in the…
OBJECTIVE: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the…
Major cardiovascular (CV) outcome trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are currently available. These agonists have proven their CV safety, in harmony with the US Food and Drug Administration (FDA) recommendation for antidiabetic drugs. The potential cardioprotective effect of incretin-based therapies is attributed to their multiple non-glycaemic actions in the CV system, including…
Cardiovascular disease (CVD) remains the predominant cause of human morbidity and mortality in developed countries. Currently, microRNAs have been investigated in many diseases as well-promising biomarkers for diagnosis, prognosis, and disease monitoring. Plenty studies have been designed so as to elucidate the properties of microRNAs in the classification and risk stratification of patients with CVD…
Cardiovascular disease (CVD) is a significant and ever-growing problem in Europe, accounting for nearly 45% of all deaths and leading to significant morbidity. Greece is one of the European Union member states that top the list of deaths due to ischemic heart disease and stroke, a fact that is mainly attributed to unfavorable changes in…
